Michael Levin, DO
Nephrology · Philadelphia, PANPI 1578524526
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $48,150 of the $54,814 with a category attached, or 87.8%. Aurinia Pharma U.S., Inc. accounts for 81.3% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2021 at $18,951 and has fallen 95.7% since, to $808 in 2025. Among nephrology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 205 payments — averaging $267.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aurinia Pharma U.S., Inc.$45K
- Vifor Pharma, Inc.$7K
- Amgen$440
- AstraZeneca$433
- ANI Pharmaceuticals, Inc.$397
- Novartis$273
- plus $2K from 21 others
What the payments were for
- Consulting fees$1,7603%
- Speaking & faculty fees$48,15088%
- Travel & lodging$1370%
- Food & beverage$4,6438%
- Education$1250%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aurinia Pharma U.S., Inc. | 45 | $44,569 |
| Vifor Pharma, Inc. | 25 | $6,745 |
| Amgen(2 entities) | 19 | $440 |
| AstraZeneca(2 entities) | 17 | $433 |
| ANI Pharmaceuticals, Inc. | 20 | $397 |
| Novartis | 11 | $273 |
| Otsuka America Pharmaceutical, Inc. | 13 | $245 |
| Boehringer Ingelheim | 4 | $242 |
| Fresenius USA Marketing, Inc. | 10 | $212 |
| Travere Therapeutics, Inc. | 3 | $163 |
| Mallinckrodt Hospital Products Inc. | 6 | $158 |
| Mallinckrodt Enterprises LLC | 2 | $125 |
| Novo Nordisk | 3 | $91 |
| Akebia Therapeutics Inc | 4 | $88 |
| Merck | 1 | $86 |
| Biohaven Pharmaceuticals, Inc. | 1 | $86 |
| Bayer | 4 | $85 |
| GSK | 3 | $76 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 5 | $73 |
| Calliditas Therapeutics US Inc. | 2 | $53 |
| Abiomed | 1 | $36 |
| Ardelyx, Inc. | 1 | $34 |
| Abbott | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Lilly USA, LLC | 1 | $18 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$54,814 in reported general payments places this provider in the 95th percentile of 586 nephrology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 71 | $302,789 |
| FarxigaDapagliflozin Propanediol | 87 | $103,535 |
| AuryxiaFerric Citrate | 59 | $100,612 |
| JardianceEmpagliflozin | 73 | $73,295 |
| Sevelamer Carbonate | 75 | $22,853 |
| TrulicityDulaglutide | 19 | $19,107 |
| RybelsusSemaglutide | 16 | $17,115 |
| Xigduo XrDapaglifloz Propaned/Metformin | 20 | $12,274 |
| SynjardyEmpagliflozin/Metformin Hcl | 11 | $10,779 |
| VeltassaPatiromer Calcium Sorbitex | 11 | $9,981 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $8,265 |
| InvokanaCanagliflozin | 12 | $6,917 |
| InvokametCanagliflozin/Metformin Hcl | 11 | $6,326 |
| Potassium Citrate ErPotassium Citrate | 33 | $4,710 |
| Clonidine | 39 | $4,060 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $212 | $302,78971 claims |
| AstraZenecaFarxiga | $433 | $103,53587 claims |
| Akebia Therapeutics IncAuryxia | $88 | $100,61259 claims |
| Boehringer IngelheimJardiance, Synjardy | $242 | $84,07484 claims |
| Lilly USA, LLCTrulicity | $18 | $19,10719 claims |
| Novo NordiskRybelsus | $91 | $17,11516 claims |
| GSKTrelegy Ellipta | $76 | $8,26512 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $397 | $1,46191 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 586 nephrology providers in Pennsylvania.
Other nephrology in Philadelphia
- Rakesh GulatiPhiladelphia$657K
- Raymond TownsendPhiladelphia$357K
- Ellie KelepourisPhiladelphia$287K
- Abdallahsassine GearaPhiladelphia$225K
- Katalin SusztakPhiladelphia$192K
- Debbie Cohen SteinPhiladelphia$112K
- Laura DemberPhiladelphia$110K
- Jonathan HoganPhiladelphia$100K
- Michael YoslovPhiladelphia$79K
- Gaia MuallemPhiladelphia$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.